Allergy Therapeutics announced that David Ball will join the Board of Allergy Therapeutics as an independent Non-Executive Director with immediate effect. David is also appointed Chair of the Board's Audit and Risk Committee. David has over 25 years of experience in financial markets, including 15 years as an equity portfolio manager and partner with Tudor Investment Corporation.

David is a chartered accountant and holds undergraduate and postgraduate degrees in engineering from Cambridge University. David William Dawson Ball, aged 55, is a director of Argonaute RNA Limited and in the previous five years, David was a director of Brainomix Limited. David does not have an interest in ordinary shares in the Company.